Lanifibranor Plus Empagliflozin Effective in T2D, MASH: Proof-of-Concept Ph2 Findings
LEGEND phase 2 interim analysis findings include significant decreases in HbA1c in poorly controlled T2D and positive effects on several markers of liver injury.
Aspirin Use among Older Adults: Daily Dose
Your daily dose of the clinical news you may have missed.
FDA Approves Aprocitentan (Tryvio) for Treatment-Resistant Hypertension in Landmark Decision
Aprocitentan is the first antihypertensive drug approved in more than 30 years that achieves its effect through a unique therapeutic pathway.
Topline Phase 3 Data Released for Elinzanetant Efficacy for Moderate-to-Severe VMS
The novel dual NK-1,3 receptor antagonist demonstrated statistically significant reduction in the frequency of moderate-to-severe VMS vs placebo.
Underrepresentation of Patients with CKD in CVD Medication Trials: Daily Dose
Merck's 21-Valent Adult-Specific Pneumococcal Vaccine Accrues New Phase 3 and Real World Data
The novel 21-valent pneumococcal vaccine remains on track for the FDA PDUFA date of June 17, 2024; Merck adds this new data to the body of positive evidence.
Would you Know Measles if You Saw It?
A case of measles is a very rare diagnosis in the 21st century, but as MMR vaccination rates fall, the cases climb. Would you recognize the signs & symptoms?
This is Measles If You've Never Seen It
Here, the 5 key signs and symptoms that characterize measles in the order of appearance.
Measles and the Collective American Memory: 3 Questions
Measles cases are edging up in the US again as MMR vaccination rates continue to decline. Have parents forgotten the Ohio outbreak of 2022? Have you? Find out, here.
Nirsevimab Effective Against RSV Hospitalization among Infants: Daily Dose
Blood-Based DNA Test Shows Sensitivity of 83% for Colorectal Cancer
Findings from the ECLIPSE clinical trial showed the blood-based cancer screening test detects 83% of people with CRC, with a specificity of 90%.
Optinose Xhance approved by FDA as first medical therapy for CRS
Now FDA approved, Optinose’s Xhance is the first nonsurgical option for chronic rhinosinusitis both with and without nasal polyps.
Dyslipidemia in American Indian Youth: Daily Dose
Madrigal's Resmetirom Wins Historic FDA Approval for Noncirrhotic NASH
Resmetirom is the first-ever drug to be approved anywhere for management of the progressive liver disease.
Plastic Debris in Carotid Plaque Linked to CV Events: Daily Dose
AstraZeneca Launches Phase 3 THARROS Trial of Breztri to Reduce Cardiopulmonary Events in COPD
THARROS is the first phase 3 RCT to evaluate an inhaled triple combination therapy for reduction of adverse cardiopulmonary events in people with COPD, says AstraZeneca.
KDIGO Releases 2024 Clinical Practice Guideline for Evaluation and Management of CKD
The KDIGO 2024 CKD Practice Guideline is the first update since the 2012 iteration and so is based on the newest research on treatment and technology available.
Aspirin Use among Older Adults Inconsistent with Current Guidelines, According to New Survey
In a survey of adults aged 50-80 years, 57% of those who reported taking aspirin regularly said they do not have a history of CVD.
Antisense Molecule against MASH from Ionis Meets Primary Endpoint in Phase 2 Trial
Ionis reports the first clinical evidence that DGAT2 inhibition-driven reduction of hepatic fat correlates with improvements in MASH histologic endpoints.
In Pregnant Women with T1D, Higher Time-in-Range Improves Maternal, Neonatal Outcomes: Daily Dose